healthday13h
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...
Discover Magazine8h
Like Ozempic, GLP-1s May Have Broader Health Benefits but Greater Risks
Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Popular weight-loss drugs linked to cognitive benefits but may pose kidney risks
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...
Daily Courier1d
Pivotal new study examines endoscopic path to maintain weight loss after stopping GLP-1 use
Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...
Medscape1mon
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration has approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide (Victoza, Novo Nordisk) to lower ...
Nature4y
G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes
In addition to impaired insulin secretion, type 2 diabetic patients also have elevated levels of glucagon, which worsens hyperglycemia by increasing glucose production by the liver. Type 2 ...